117 related articles for article (PubMed ID: 32815673)
21. Prostate Cancer Predictive Simulation Modelling, Assessing the Risk Technique (PCP-SMART): Introduction and Initial Clinical Efficacy Evaluation Data Presentation of a Simple Novel Mathematical Simulation Modelling Method, Devised to Predict the Outcome of Prostate Biopsy on an Individual Basis.
Spyropoulos E; Kotsiris D; Spyropoulos K; Panagopoulos A; Galanakis I; Mavrikos S
Clin Genitourin Cancer; 2017 Feb; 15(1):129-138.e1. PubMed ID: 27460552
[TBL] [Abstract][Full Text] [Related]
22. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
[TBL] [Abstract][Full Text] [Related]
23. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
[TBL] [Abstract][Full Text] [Related]
24. [Total PSA, PSA density and biopsy Gleason score in predicting the pathologic stage of prostate cancer].
Liu S; Lü JJ; Fu Q; Zhang H; Gao DX; Liu Z
Zhonghua Nan Ke Xue; 2010 May; 16(5):415-9. PubMed ID: 20684321
[TBL] [Abstract][Full Text] [Related]
25. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
[TBL] [Abstract][Full Text] [Related]
26. The clinical value of the ratio of free prostate specific antigen to total prostate specific antigen.
Dalva I; Akan H; Yildiz O; Telli C; Bingol N
Int Urol Nephrol; 1999; 31(5):675-80. PubMed ID: 10755359
[TBL] [Abstract][Full Text] [Related]
27. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
Okegawa T; Noda H; Nutahara K; Higashihara E
Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
[TBL] [Abstract][Full Text] [Related]
28. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.
Lazzeri M; Haese A; de la Taille A; Palou Redorta J; McNicholas T; Lughezzani G; Scattoni V; Bini V; Freschi M; Sussman A; Ghaleh B; Le Corvoisier P; Alberola Bou J; Esquena Fernández S; Graefen M; Guazzoni G
Eur Urol; 2013 Jun; 63(6):986-94. PubMed ID: 23375961
[TBL] [Abstract][Full Text] [Related]
29. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
Chen ZD; Wei SM; Cai SL
Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):593-5. PubMed ID: 15265401
[TBL] [Abstract][Full Text] [Related]
30. PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience.
Merola R; Tomao L; Antenucci A; Sperduti I; Sentinelli S; Masi S; Mandoj C; Orlandi G; Papalia R; Guaglianone S; Costantini M; Cusumano G; Cigliana G; Ascenzi P; Gallucci M; Conti L
J Exp Clin Cancer Res; 2015 Feb; 34(1):15. PubMed ID: 25651917
[TBL] [Abstract][Full Text] [Related]
31. [Usefulness of free PSA/total PSA ratio in the diagnosis of prostatic cancer in symptomatic patients with PSA levels ranging from 2.5 to 20 ng/ml].
Herranz Amo F; Verdú Tartajo F; Díez Cordero JM; Leal Hernández F; Bielsa Carrillo A; García Burgos J; Subirá Ríos D
Actas Urol Esp; 2000 Jan; 24(1):24-30. PubMed ID: 10746371
[TBL] [Abstract][Full Text] [Related]
32. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
[TBL] [Abstract][Full Text] [Related]
33. Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination.
Chiu PK; Teoh JY; Lee WM; Yee CH; Chan ES; Hou SM; Ng CF
Investig Clin Urol; 2016 Sep; 57(5):336-42. PubMed ID: 27617315
[TBL] [Abstract][Full Text] [Related]
34. Does baseline total testosterone improve the yielding of prostate cancer screening?
Botelho F; Pina F; Figueiredo L; Cruz F; Lunet N
Eur J Cancer; 2012 Jul; 48(11):1657-63. PubMed ID: 22342552
[TBL] [Abstract][Full Text] [Related]
35. [Aggressiveness and extent of prostatic inflammation relates with serum PSA levels in type IV prostatitis].
Man LB; Li GZ; Huang GL; Wang JW; Liu BY
Zhonghua Nan Ke Xue; 2012 Aug; 18(8):710-4. PubMed ID: 22934516
[TBL] [Abstract][Full Text] [Related]
36. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL.
Okegawa T; Kinjo M; Watanabe K; Noda H; Kato M; Miyata A; Murata A; Yoshii M; Nutahara K; Higashihara E
BJU Int; 2000 Apr; 85(6):708-14. PubMed ID: 10759671
[TBL] [Abstract][Full Text] [Related]
37. The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6.
Wang H; Gu L; Wu Y; Feng D; Duan J; Wang X; Huang Y; Wu S; Chen J; Luo G; Zhang X
BMC Cancer; 2017 Sep; 17(1):629. PubMed ID: 28874127
[TBL] [Abstract][Full Text] [Related]
38. [The detection rate of prostate cancer in different prostate-specific antigen (PSA) levels in Chinese men].
Li M; Na YQ
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(1):16-8. PubMed ID: 18346372
[TBL] [Abstract][Full Text] [Related]
39. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran.
Safarinejad MR
Ann Oncol; 2006 Jul; 17(7):1166-71. PubMed ID: 16684791
[TBL] [Abstract][Full Text] [Related]
40. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
